Search

Displaying results 9361 - 9370 of 9431 in total
  1. Drug

    Col-Treg

    go.drugbank.com/drugs/DB18451
    Experimental

    Col-Treg is an autologous T-cell therapy comprising type I regulatory T-cells specific for human type II collagen.[A261635]

    Synonyms: Purified autologous type 1 regulatory T lymphocytes specific for human type II collagen
  2. Drug

    MDR-101

    go.drugbank.com/drugs/DB18513
    Investigational

    MDR-101 is a CD34+ hematopoietic stem and progenitor cells with CD3+ T-cells

  3. Drug

    FCR001

    go.drugbank.com/drugs/DB18595
    Investigational

    FCR001 is a somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells.

  4. Drug

    CTX120

    go.drugbank.com/drugs/DB18625
    Investigational

    CTX120 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting B-cell maturation antigen.

    Synonyms: allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting B-cell maturation antigen
  5. Drug

    CTX110

    go.drugbank.com/drugs/DB18626
    Investigational

    CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.

    Synonyms: allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting CD19 antigen
  6. Drug

    Zedenoleucel

    go.drugbank.com/drugs/DB18639
    Investigational

    MT-401 is an allogeneic multi-tumor-associated antigen-specific T-cell therapy.

  7. Drug

    Melanoma antigen recognized by T-cells 1

    go.drugbank.com/drugs/DB15081
    Investigational

    Melanoma antigen recognized by T-cells 1 is under investigation in clinical trial NCT01748747 (Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

    Synonyms: Melanoma antigen recognized by T-cells 1
  8. Drug

    Lacutamab

    go.drugbank.com/drugs/DB15322
    Investigational

    Lacutamab is under investigation in clinical trial NCT02593045 (Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)).

  9. Drug

    L-arginine

    go.drugbank.com/drugs/DB17289
    ApprovedInvestigationalNutraceutical

    Mixtures: Clinimix E, Clinimix E
  10. Drug

    Maveropepimut-S

    go.drugbank.com/drugs/DB17339
    Investigational

    Maveropepimut-S is a T cell activating immunotherapy.